Cardiol Therapeutics Inc. (CRDL)
CRDL Stock Price Chart
Explore Cardiol Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze CRDL price movements and trends.
CRDL Company Profile
Discover essential business fundamentals and corporate details for Cardiol Therapeutics Inc. (CRDL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
15 Jan 2019
Employees
18.00
Website
https://www.cardiolrx.comCEO
David G. Elsley
Description
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
CRDL Financial Timeline
Browse a chronological timeline of Cardiol Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.08.
Earnings released on 11 May 2026
EPS came in at -$0.07 matching the estimated -$0.07.
Earnings released on 30 Mar 2026
EPS came in at -$0.05 surpassing the estimated -$0.09 by +43.37%.
Earnings released on 13 Nov 2025
EPS came in at -$0.09 matching the estimated -$0.09.
Earnings released on 14 Aug 2025
EPS came in at -$0.07 surpassing the estimated -$0.11 by +36.36%.
Earnings released on 14 May 2025
EPS came in at -$0.07 surpassing the estimated -$0.09 by +22.22%.
Earnings released on 31 Mar 2025
EPS came in at -$0.07 surpassing the estimated -$0.08 by +12.50%.
Earnings released on 14 Nov 2024
EPS came in at -$0.13 falling short of the estimated -$0.10 by -30.00%.
Earnings released on 12 Aug 2024
EPS came in at -$0.07 surpassing the estimated -$0.10 by +30.00%.
Earnings released on 14 May 2024
EPS came in at -$0.10 falling short of the estimated -$0.06 by -66.67%.
Earnings released on 1 Apr 2024
EPS came in at -$0.09 surpassing the estimated -$0.09 by +0.60%.
Earnings released on 14 Nov 2023
EPS came in at -$0.07 surpassing the estimated -$0.09 by +20.75%.
Earnings released on 11 Aug 2023
EPS came in at -$0.09 surpassing the estimated -$0.09 by +4.56%.
Earnings released on 15 May 2023
EPS came in at -$0.08 surpassing the estimated -$0.08 by +1.64%.
Earnings released on 27 Mar 2023
EPS came in at -$0.09 falling short of the estimated -$0.06 by -52.49%.
Earnings released on 10 Nov 2022
EPS came in at -$0.10 surpassing the estimated -$0.10 by +4.56%.
Earnings released on 10 Aug 2022
EPS came in at -$0.08 surpassing the estimated -$0.10 by +20.74%.
Earnings released on 16 May 2022
EPS came in at -$0.11 surpassing the estimated -$0.14 by +19.03%.
Earnings released on 23 Mar 2022
EPS came in at -$0.09 surpassing the estimated -$0.11 by +18.68%.
Earnings released on 15 Nov 2021
EPS came in at -$0.18 .
Earnings released on 17 Aug 2021
EPS came in at -$0.13 , while revenue for the quarter reached $63.54k .
CRDL Stock Performance
Access detailed CRDL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
